|Bid||21.6000 x 100|
|Ask||22.3000 x 100|
|Day's Range||21.6300 - 22.1400|
|52 Week Range||18.2800 - 30.8000|
|PE Ratio (TTM)||-306.39|
|Earnings Date||Aug 2, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||28.44|
Q1 2017 NxStage Medical Inc Earnings Call
"Early customer and patient feedback in the UK on our next generation system has been very positive, validating many of the benefits we expected," said Joseph E. Turk, president of NxStage Medical, Inc. "We are very excited to bring these new features and capabilities that are designed to significantly improve our patients' therapy experience to the US market. The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis.
A cut in 2017 outlook for home dialysis products has investors disappointed.